Am Law 100 firm Polsinelli has hired renowned attorney Chad A. Landmon to chair the firm’s Hatch-Waxman & Biologics Practice. Joining the firm’s Washington, D.C. office, Landmon is a first chair trial lawyer who guides clients through clearing both Hatch-Waxman pharmaceutical and biologics patent litigation and the Food and Drug Administration (FDA) approval hurdles, enabling clients to bring their products to market efficiently and profitably. Landmon has litigated more than 60 cases in the past decade alone, and he has advised on nine of the top 10 generic drugs by cost savings and nearly half of the top 100 by sales volume.

“Chad is a recognized star in the industry, and his background in pharmaceuticals litigation, as well as FDA, provides him with a unique dual practice that is highly regarded in the market and will be a great asset to our clients,” said Patrick C. Woolley, Intellectual Property Department Chair. “We are very excited he has joined our team. His extensive experience with the FDA elevates our existing team as clients are facing increasingly uncertain times in a post-Chevron world.”

“Polsinelli has extensive technical expertise in its deep IP bench that is known to be one of the largest in the country. Biosimilars, for example, is a highly complex field that is perfectly suited for a firm like Polsinelli that has the resources to serve my clients nationwide with a team of scientists and PhDs through the entire lifecycle,” Landmon said. “I was also impressed that Polsinelli has the ability to deploy AI technology to benefit clients, which is becoming increasingly important in intellectual property. I am thrilled to be here and join this team.”

Landmon is another addition to Polsinelli’s life sciences team, following a wave of new attorneys to join the firm, including Brian Larivee, Andrew Merken, Bill Di Bianca and Jordan Riviello in recent months.

Landmon graduated summa cum laude from the University of Connecticut before completing his J.D. with honors at the University of Connecticut School of Law. For the past 25 years, he has been representing manufacturers of pharmaceuticals, biologics, medical devices and human tissue products with billions of dollars in annual sales. Additionally, he handles cases involving the cross-section of antitrust and patent law. His experience extends to navigating challenges posed by the Biologics Price Competition and Innovation Act. He is recognized among the world’s leading patent litigators by IAM Patent 1000, Benchmark Litigation and Law360.

Polsinelli’s multidisciplinary pharmaceuticals team includes trial attorneys, FDA and antitrust counsel, patent attorneys and agents. They are skilled courtroom advocates, and they bring to bear their team members’ backgrounds in chemistry, organic chemistry, biochemistry, biology, pharmacy, medicine, molecular biology, microbiology, neuroscience, pharmacology, genetics, immunology and molecular biophysics, among others. The team has knowledge and experience in cases related to compositions and APIs, formulations (e.g., oral dosage forms, controlled release, ODTs, transdermal, topical, ophthalmic, transmucosal, parenteral, etc.), methods of use, polymorphs, enantiomers, drug delivery devices (including combination products), and methods of manufacture, including cell lines and expression systems. Polsinelli’s attorneys have first-chair experience litigating cases on behalf of pharmaceutical companies in key venues, including the federal courts in Delaware, New Jersey, the Eastern District of Texas, the Southern District of New York, and the Northern District of Illinois.